Univariate and multivariable analysis of risk factors for CVC-related recurrent VTE or additional catheter placements
| . | CVCs without recurrent VTE (n = 492), % . | CVCs with recurrent VTE (n = 58), % . | Univariate analysis OR (95% CI) . | Multivariable analysis OR (95% CI) . |
|---|---|---|---|---|
| Age at CVC placement | ||||
| <1 | 237 (48) | 32 (55) | 1.83 (0.66, 5.06) | 1.11 (0.37, 3.33) |
| 1-5 | 137 (28) | 18 (31) | 1.77 (0.61, 5.12) | 1.23 (0.38, 3.95) |
| 5-12 | 67 (14) | 5 (9) | Reference | Reference |
| >12 | 51 (10) | 3 (5) | 0.79 (0.18, 3.55) | 0.67 (0.14, 3.24) |
| Sex | ||||
| Male | 260 (53) | 29 (50) | Reference | Excluded |
| Female | 232 (47) | 29 (50) | 1.12 (0.65, 1.94) | |
| Race | ||||
| White | 262 (53) | 22 (38) | Reference | Excluded |
| Black | 100 (20) | 22 (38) | 2.66 (1.42, 4.98) | |
| Asian | 16 (3) | 2 (3) | 1.50 (0.31, 7.29) | |
| Other | 114 (23) | 12 (21) | 1.28 (0.63, 2.61) | |
| CVC type | ||||
| Peripherally inserted central catheter | 310 (63) | 44 (76) | 1.45 (0.69, 3.02) | 1.53 (0.70, 3.34) |
| Tunneled catheter | 80 (16) | 4 (7) | 0.51 (0.15, 1.71) | 0.63 (0.17, 2.38) |
| Nontunneled catheter | 102 (21) | 10 (17) | Reference | Reference |
| Additional CVC placed | ||||
| 1 | 214 (44) | 25 (43) | 1.04 (0.46, 2.37) | Excluded |
| 2 | 124 (25) | 13 (22) | 0.93 (0.37, 2.33) | |
| 3 | 64 (13) | 10 (17) | 1.39 (0.52, 3.71) | |
| 4 or higher | 90 (18) | 10 (17) | Reference | |
| Chronic medical condition | ||||
| Congenital heart disease | 103 (21) | 20 (34) | 1.99 (1.12, 3.53) | 3.02 (1.59, 5.73) |
| Total parenteral nutrition dependence | 100 (20) | 24 (41) | 2.78 (1.62, 4.78) | 3.08 (1.65, 5.74) |
| Cancer | 48 (10) | 1 (2) | 0.16 (0.02, 1.21) | 0.59 (0.06, 5.39) |
| Renal | 51 (10) | 5 (9) | 0.82 (0.30, 2.20) | Others/reference |
| Hyperinsulinemia | 23 (5) | 2 (3) | 0.72 (0.23, 2.32) | |
| Cystic fibrosis | 11 (2) | 1 (2) | 0.77 (0.09, 6.72) | |
| Autoimmune disease | 19 (4) | 1 (2) | 0.40 (0.03, 4.79) | |
| Gastrointestinal autoimmune disease | 34 (7) | 2 (3) | 0.45 (0.08, 2.38) | |
| Sickle cell disease | 3 (1) | 1 (2) | 2.86 (0.24, 33.48) | |
| None | 29 (6) | 1 (2) | 0.28 (0.03, 2.34) | |
| Congenital thrombophilia* | ||||
| Present | 51 (10) | 8 (14) | 1.69 (0.70, 4.12) | 1.81 (0.74, 4.40) |
| Absent | 301 (61) | 37 (64) | 1.33 (0.69, 2.57) | 1.63 (0.81, 3.26) |
| Not assessed | 140 (28) | 13 (22) | Reference | Reference |
| Acute clinical issue | ||||
| Recent surgery (<30 d) | 104 (21) | 17 (29) | 1.55 (0.84, 2.87) | Excluded |
| Active infection | 53 (11) | 5 (9) | 0.67 (0.28, 1.59) | |
| Protein-losing process | 33 (7) | 2 (3) | 0.50 (0.11, 2.23) | |
| Prothrombotic medication | 21 (4) | 0 (0) | 0† | |
| Secondary prophylaxis | ||||
| Prophylactic dosing | 84 (17) | 9 (16) | 0.60 (0.28, 1.26) | 0.61 (0.28, 1.30) |
| Full dosing | 282 (57) | 22 (38) | 0.40 (0.23, 0.71) | 0.35 (0.19, 0.65) |
| No anticoagulation | 141 (29) | 27 (47) | Reference | Reference |
| . | CVCs without recurrent VTE (n = 492), % . | CVCs with recurrent VTE (n = 58), % . | Univariate analysis OR (95% CI) . | Multivariable analysis OR (95% CI) . |
|---|---|---|---|---|
| Age at CVC placement | ||||
| <1 | 237 (48) | 32 (55) | 1.83 (0.66, 5.06) | 1.11 (0.37, 3.33) |
| 1-5 | 137 (28) | 18 (31) | 1.77 (0.61, 5.12) | 1.23 (0.38, 3.95) |
| 5-12 | 67 (14) | 5 (9) | Reference | Reference |
| >12 | 51 (10) | 3 (5) | 0.79 (0.18, 3.55) | 0.67 (0.14, 3.24) |
| Sex | ||||
| Male | 260 (53) | 29 (50) | Reference | Excluded |
| Female | 232 (47) | 29 (50) | 1.12 (0.65, 1.94) | |
| Race | ||||
| White | 262 (53) | 22 (38) | Reference | Excluded |
| Black | 100 (20) | 22 (38) | 2.66 (1.42, 4.98) | |
| Asian | 16 (3) | 2 (3) | 1.50 (0.31, 7.29) | |
| Other | 114 (23) | 12 (21) | 1.28 (0.63, 2.61) | |
| CVC type | ||||
| Peripherally inserted central catheter | 310 (63) | 44 (76) | 1.45 (0.69, 3.02) | 1.53 (0.70, 3.34) |
| Tunneled catheter | 80 (16) | 4 (7) | 0.51 (0.15, 1.71) | 0.63 (0.17, 2.38) |
| Nontunneled catheter | 102 (21) | 10 (17) | Reference | Reference |
| Additional CVC placed | ||||
| 1 | 214 (44) | 25 (43) | 1.04 (0.46, 2.37) | Excluded |
| 2 | 124 (25) | 13 (22) | 0.93 (0.37, 2.33) | |
| 3 | 64 (13) | 10 (17) | 1.39 (0.52, 3.71) | |
| 4 or higher | 90 (18) | 10 (17) | Reference | |
| Chronic medical condition | ||||
| Congenital heart disease | 103 (21) | 20 (34) | 1.99 (1.12, 3.53) | 3.02 (1.59, 5.73) |
| Total parenteral nutrition dependence | 100 (20) | 24 (41) | 2.78 (1.62, 4.78) | 3.08 (1.65, 5.74) |
| Cancer | 48 (10) | 1 (2) | 0.16 (0.02, 1.21) | 0.59 (0.06, 5.39) |
| Renal | 51 (10) | 5 (9) | 0.82 (0.30, 2.20) | Others/reference |
| Hyperinsulinemia | 23 (5) | 2 (3) | 0.72 (0.23, 2.32) | |
| Cystic fibrosis | 11 (2) | 1 (2) | 0.77 (0.09, 6.72) | |
| Autoimmune disease | 19 (4) | 1 (2) | 0.40 (0.03, 4.79) | |
| Gastrointestinal autoimmune disease | 34 (7) | 2 (3) | 0.45 (0.08, 2.38) | |
| Sickle cell disease | 3 (1) | 1 (2) | 2.86 (0.24, 33.48) | |
| None | 29 (6) | 1 (2) | 0.28 (0.03, 2.34) | |
| Congenital thrombophilia* | ||||
| Present | 51 (10) | 8 (14) | 1.69 (0.70, 4.12) | 1.81 (0.74, 4.40) |
| Absent | 301 (61) | 37 (64) | 1.33 (0.69, 2.57) | 1.63 (0.81, 3.26) |
| Not assessed | 140 (28) | 13 (22) | Reference | Reference |
| Acute clinical issue | ||||
| Recent surgery (<30 d) | 104 (21) | 17 (29) | 1.55 (0.84, 2.87) | Excluded |
| Active infection | 53 (11) | 5 (9) | 0.67 (0.28, 1.59) | |
| Protein-losing process | 33 (7) | 2 (3) | 0.50 (0.11, 2.23) | |
| Prothrombotic medication | 21 (4) | 0 (0) | 0† | |
| Secondary prophylaxis | ||||
| Prophylactic dosing | 84 (17) | 9 (16) | 0.60 (0.28, 1.26) | 0.61 (0.28, 1.30) |
| Full dosing | 282 (57) | 22 (38) | 0.40 (0.23, 0.71) | 0.35 (0.19, 0.65) |
| No anticoagulation | 141 (29) | 27 (47) | Reference | Reference |